- Adding personalized cancer vaccine to Keytruda keeps more melanoma patients in remission.
- 79% of people who received both treatments stayed cancer-free 18 months later.
- Companies plan to test the combination in other cancers where Keytruda is already used.
Merck-Moderna Vaccine Helps Keep Patients Free From Skin Cancer
Adding a personalized cancer vaccine to the blockbuster drug Keytruda kept more melanoma patients in remission than the immune therapy alone, co-developers Moderna Inc. and Merck & Co. said in their first detailed presentation of a key study.
Angelica Peebles
/cloudfront-us-east-2.images.arcpublishing.com/reuters/RCWZE2OK3BNCJNRVFOS74NYF7M.jpg)
